Alimera Sciences Inc (ALIM)
5.54
+0.01
(+0.18%)
USD |
NASDAQ |
Jun 28, 16:00
5.54
0.00 (0.00%)
After-Hours: 20:00
Alimera Sciences SG&A Expense (Annual): 46.48M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 46.48M |
| December 31, 2022 | 38.86M |
| December 31, 2021 | 35.84M |
| December 31, 2020 | 32.04M |
| December 31, 2019 | 38.96M |
| December 31, 2018 | 38.04M |
| December 31, 2017 | 36.25M |
| December 31, 2016 | 44.69M |
| December 31, 2015 | 42.28M |
| Date | Value |
|---|---|
| December 31, 2014 | 27.46M |
| December 31, 2013 | 25.42M |
| December 31, 2012 | 14.10M |
| December 31, 2011 | 14.31M |
| December 31, 2010 | 9.49M |
| December 31, 2009 | 4.159M |
| December 31, 2008 | 6.317M |
| December 31, 2007 | 4.153M |
| December 31, 2006 | 3.644M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
32.04M
Minimum
2020
46.48M
Maximum
2023
38.43M
Average
38.86M
Median
2022
SG&A Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 161.70M |
| Alnylam Pharmaceuticals Inc | 795.65M |
| G1 Therapeutics Inc | 71.13M |
| Reneo Pharmaceuticals Inc | 26.44M |
| Sarepta Therapeutics Inc | 481.87M |